Publications by authors named "S Urien"
Background: Limited data exist on how continuous renal replacement therapy (CRRT) affects antimicrobial dosing in pediatric patients. This study examined the impact of pediatric CRRT parameters on the pharmacokinetics (PK) of meropenem, piperacillin, and tazobactam using an in vitro CRRT model.
Research Design And Methods: An in vitro CRRT model with a pediatric ST60 circuit was used to assess antimicrobial clearance during continuous veno-venous hemodialysis (CVVHD) or hemofiltration (CVVH).
Article Synopsis
- The study aimed to analyze how paracetamol and its metabolites behave in extremely preterm neonates during treatment for patent ductus arteriosus and to identify factors influencing variability in individual responses.
- Thirty preterm neonates receiving paracetamol were monitored, revealing that the drug was mostly metabolized through the sulfation pathway, which decreased with gestational age, while the glucuronidation pathway increased.
- The results showed no link between the level of drug exposure and clinical outcomes or liver function indicators, suggesting that the dosages used might already achieve optimal effectiveness for ductus closure.
Aims: Vigabatrin is an antiepileptic drug used to treat some forms of severe epilepsy in children. The main adverse effect is ocular toxicity, which is related to the cumulative dose. The aim of the study is to identify an acceptable exposure range, both through the development of a population pharmacokinetic model of vigabatrin in children enabling us to calculate patient exposure and through the study of therapeutic response.
View Article and Find Full Text PDFArticle Synopsis
- A study on the pharmacokinetics of lumacaftor/ivacaftor in children with cystic fibrosis (CF) highlights the importance of optimizing treatment based on individual differences.
- Factors like body weight and liver function were found to significantly affect drug levels in patients, showing that each child may process the medication differently.
- The research suggests that personalized dose adjustments and therapeutic drug monitoring could enhance treatment effectiveness in this vulnerable population.
Complement activation has shown a role in murine models of graft-versus-host disease (GVHD) and in endothelial complications after allogeneic hematopoietic cell transplantation (allo-HSCT). However, its impact on post-transplant outcomes has not been so far fully elucidated. Here, we conducted a prospective multicentric trial (NCT01520623) performing serial measurements of complement proteins, regulators, and CH50 activity for 12 weeks after allo-HSCT in 85 patients receiving a myeloablative conditioning (MAC) regimen for various hematological malignancies.
View Article and Find Full Text PDF